Non-alcoholic steatohepatitis

Non-alcoholic steatohepatitis belongs to the spectrum of metabolic-associated fatty liver diseases charac-terized by steatosis linked to obesity, diabetes, metabolic syndrome, dyslipidemia and immune-mediated disorders. The main features of MAFLD include high prevalence, heterogeneity, complexity and dyna-mic disease. Pruritus and asthenia are the main clinical manifestation that impact on quality of life and patient-reported outcomes. Biochemical or imagen-based non-invasive test have been implemented in the diagnostic process. Liver biopsy remains as the gold standard. Therapeutic options included life-style intervention. Mediterranean hypocaloric Diet to lose weight, exercise to fight sarcopenia and alcohol abs-tinence. In non-responders, drug-therapy focusing on obesity, diabetes and fibrosis using sequentially or combined to promote steatosis, inflammation and fibrosis regression.(c) 2022 Published by Elsevier Espana, S.L.U.

Automated summary

Non-alcoholic steatohepatitis is a part of the spectrum of metabolic-associated fatty liver diseases, which is characterized by fatty degeneration linked to obesity, diabetes, metabolic syndrome, dyslipidemia, and immune-mediated disorders. This disease has high prevalence, heterogeneity, complexity, and dynamic nature, with pruritus and asthenia as the main clinical manifestations. Diagnosis can be aided by biochemical or imaging-based non-invasive tests, although liver biopsy remains the gold standard. Lifestyle changes and drug therapy are the main treatment options.